Pasireotide-related paper on acromegaly radiotherapy published in Pituitary

A new publication discussing acromegaly management was listed in the journal Pituitary on October 16, 2026. The article is titled "Should radiotherapy be repositioned in the contemporary management of acromegaly?" This publication is associated with pasireotide, an approved compound used in acromegaly treatment contexts. No findings, outcomes, or efficacy data from the publication were provided alongside this listing. The entry reflects only the title, journal, and publication date as recorded. No additional details regarding study design, patient population, or conclusions are included here. Readers interested in the full content and analysis of the article are encouraged to consult the publication directly through the journal Pituitary. This brief serves only to note that the publication has become available and does not characterize or summarize its content beyond the title provided. For broader context on pasireotide, including its regulatory status and general background, readers can refer to the compound overview.